Cardiac Troponin I Concentration May Predict Mortality
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 10, 2023 -- Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart.
Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.
Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10 cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.
"These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Time-Dependent Probabilities of Favorable Outcomes Examined After CPR
THURSDAY, Feb. 8, 2024 -- For patients with in-hospital cardiac arrest, the time-dependent probabilities of favorable outcomes decrease with duration of cardiopulmonary...
Higher Survival Rates Seen for Overdose-Attributable Cardiac Arrest
MONDAY, Feb. 5, 2024 -- For patients presenting with nonshockable rhythm, those with overdose-attributable out-of-hospital cardiac arrest (OD-OHCA) have higher survival rates with...
Lasting Benefits Seen for Cardiac Resynchronization Therapy With Defibrillator
THURSDAY, Jan. 18, 2024 -- Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.